Teva Pharma (TEVA) Launches Generic Gleevec Tablets in U.S.

August 5, 2016 8:05 AM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of the generic equivalent to Gleevec®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multiple indications approved by the FDA.

Teva remains committed to strengthening its generics business with continued investment in new and diverse, high quality products. With nearly 375 generic medicines available, Teva has one of the largest portfolios of FDA-approved generic products on the market. The addition of this product to Teva’s oncology portfolio allows Teva to continue to grow in this therapeutic area.

Imatinib mesylate tablets had annual sales of approximately $2.42 billion in the United States, according to IMS data as of May 2016.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Related Entities

Definitive Agreement

Add Your Comment